title: Short-term clinical efficacy of percutaneous irreversible electroporation combined with allogeneic natural killer cell for treating metastatic pancreatic cancer.
abstract: This study was to determine how the short-term clinical efficacy of irreversible electroporation (IRE) combined with allogeneic natural killer (NK) cell therapy for treating metastatic pancreatic cancer. Between March and December 2016, we enrolled 40 patients who met the enrollment criteria and assigned them to two groups: simple IRE (IRE group, n=20) and IRE plus allogeneic NK cell therapy (IRE-NK, n=20). We evaluated immune function changes, quality of life, clinical response, and other related indicators. Combining allogeneic NK cells with IRE had a synergistic effect, not only enhancing the immune function of the patients, but also reducing the expression of carbohydrate antigen 19-9 (CA19-9) and CA242 and significantly exhibiting good short-term outcome and improving the quality of life of the patients. This is the first clinical trial to combine allogeneic NK cells with IRE for treating metastatic pancreatic cancer, and proves the safety and efficacy of the treatment.
authors.affiliation: Department of Biological Treatment Center, Fuda Cancer Hospital, Jinan University School of Medicine, China; Fuda Cancer Institute, Guangzhou, China.
authors.forename: Mao
authors.initials: M
authors.lastname: Lin
authors.affiliation: Department of Biological Treatment Center, Fuda Cancer Hospital, Jinan University School of Medicine, China.
authors.forename: Shuzhen
authors.initials: S
authors.lastname: Liang
authors.affiliation: Department of Biological Treatment Center, Fuda Cancer Hospital, Jinan University School of Medicine, China.
authors.forename: Xiaohua
authors.initials: X
authors.lastname: Wang
authors.affiliation: Department of Biological Treatment Center, Fuda Cancer Hospital, Jinan University School of Medicine, China.
authors.forename: Yinqing
authors.initials: Y
authors.lastname: Liang
authors.affiliation: Hank Bioengineering Co., Ltd, Shenzhen, China.
authors.forename: Mingjie
authors.initials: M
authors.lastname: Zhang
authors.affiliation: Department of Biological Treatment Center, Fuda Cancer Hospital, Jinan University School of Medicine, China; Fuda Cancer Institute, Guangzhou, China. Electronic address: linmaogz@163.com.
authors.forename: Jibing
authors.initials: J
authors.lastname: Chen
authors.affiliation: Department of Biological Treatment Center, Fuda Cancer Hospital, Jinan University School of Medicine, China; Fuda Cancer Institute, Guangzhou, China; Department of Oncology, Fuda Cancer Hospital, Jinan University School of Medicine, China. Electronic address: 18922210657@163.com.
authors.forename: Lizhi
authors.initials: L
authors.lastname: Niu
authors.affiliation: Department of Biological Treatment Center, Fuda Cancer Hospital, Jinan University School of Medicine, China; Fuda Cancer Institute, Guangzhou, China.
authors.forename: Kecheng
authors.initials: K
authors.lastname: Xu
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015295:Antigens, Tumor-Associated, Carbohydrate / Q000235:genetics / Q000378:metabolism; D018395:CA-19-9 Antigen / Q000235:genetics / Q000378:metabolism; D019496:Cancer Vaccines / Q000276:immunology*; D003131:Combined Modality Therapy; D053672:Electrochemotherapy; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D016219:Immunotherapy, Adoptive / Q000379:methods*; D007694:Killer Cells, Natural / Q000276:immunology* / Q000637:transplantation; D008875:Middle Aged; D009362:Neoplasm Metastasis; D010190:Pancreatic Neoplasms / Q000276:immunology / Q000628:therapy*; D011446:Prospective Studies; D014184:Transplantation, Homologous; D016896:Treatment Outcome
chemical_list: D015295:Antigens, Tumor-Associated, Carbohydrate; C074601:CA 242 antigen; D018395:CA-19-9 Antigen; D019496:Cancer Vaccines
keywords: Clinical efficacy; Clinical trial; NK cell; Pancreatic cancer; Percutaneous irreversible electroporation; Short-term